Any estimates on how much additional revenue will be possible with the BLA label expansion? Logic would tell me that approval should mean a pop but it could also be one of those sell on the news type events, although the eternal optimist in me is expecting it to go higher with approval and exceed its all time high. Personally I wouldn't be surprised to see 60's shortly after approval as long as the overall market doesn't tank. I am also hopeful that we get news before the 8/15 deadline since it seems as if that has been happening more lately.
SGEN is one of those rare biotech stocks IMO that even though the unforeseen can happen, it still seems to me to be cheap with its pipeline and success with Adcentris. The BB's kept buying and now hold a very large chunk of shares and if it is good enough for them, it is good enough for me. I fully expect a buy out in the next 3-5 years at substantially higher prices. If RCPT can be purchased for more than SGEN's current market cap, what is our true potential in 3-5 years? RCPT goes from under $35 to over $30 in a year with its buyout price set at $7.2 billion with no approved drugs? We have an approved drug, how many partnerships, how many ongoing phase 1, 2, and 3 trials and are valued at less?
I have been a believer in SGEN for many years and it represents my single largest investment and I figure some day in the next couple of years if it stays independent that long, it alone could finance my kids education as well as a comfortable retirement, especially since I have most of my shares in Roth IRA accounts. GLTA and let's hope the FDA does the correct thing, and does it early, and expands the use of Adcentris. The other big hope is that the street treats it as good news and not a reason to sell on the news.